Tendering and biosimilars: what role for value-added services?-Reference-Cited by-同舟云学术

Tendering and biosimilars: what role for value-added services?

Published:2019-12-22 Issue:1 Volume:8 Page:1705120
ISSN:2001-6689
Container-title:Journal of Market Access & Health Policy
language:en
Short-container-title:Journal of Market Access & Health Policy

Author:

Simoens Steven¹^ORCID,Cheung Raymond²

Affiliation:

1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

2. Medical Affairs, Inflammation and Immunology, Innovative Medicines Business, Pfizer Inc, New York, NY, USA

Funder

Pfizer

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/20016689.2019.1705120

Reference47 articles.

1. Leopold C, Habl C, Vogler S. Tendering of pharmaceuticals in EU member states and EEA countries. Results from the country survey. 2008. [cited 2019 Feb 20]. Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/Final_Report_Tendering_June_08_7.pdf

2. Drug tendering: drug supply and shortage implications for the uptake of biosimilars

3. HighPoint Solutions. An IQVIA company. Tendering in the procurement environment. 2016. [cited 2019 May 9]. Available from: http://blog.highpointsolutions.com/tendering-in-the-procurement-environment

4. Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?

5. Beyond the pill: The move towards value-added services in the pharmaceutical industry

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective;Expert Review of Pharmacoeconomics & Outcomes Research;2024-01-10

2. A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply;Frontiers in Medicine;2023-10-30

3. A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report;Value in Health;2023-08

4. The landscape of biosimilars in Saudi Arabia: preparing for the next decade;Expert Opinion on Biological Therapy;2023-07-28

5. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR);British Journal of Dermatology;2023-04-05